eCase - HIV Prevention

Overview of HIV Prevention

Released: September 17, 2020

Expiration: September 16, 2021

Activity Information

Activity

Progress

Course Completed

BACK | NEXT

Introduction Behavioral Modifications Male Condoms Female Barrier Devices and Hormonal Contraception Treatment of Sexually Transmitted Diseases and HIV Acquisition Male Circumcision Nonspecific Microbicides Pre-Exposure Prophylaxis Antiretroviral Therapy for Prevention Preventing HIV Transmission to Uninfected Partners in Women Attempting Conception Vaccines for HIV Prevention Building a Combination Approach to HIV Prevention Primary Care Essentials References

ARV PrEP for HIV infection can be delivered orally or topically as a gel, film, suppository, or sustained-release intravaginal ring.³³In 2016, the WHO released updated guidance on PrEP with a recommendation that oral tenofovir DF–containing PrEP be offered to individuals at substantial risk of acquiring HIV as an additional prevention option in combination with other preventive strategies.⁷² The recommendations provisionally defined substantial HIV infection risk as an HIV incidence higher than 3/100 person-years without use of PrEP. Populations identified as having such risk include certain subgroups of MSM, transgender women in multiple settings, and heterosexual women and men who have sex with partners who have HIV and are not receiving treatment or who have not been diagnosed. The guidelines also note that these new recommendations allow for offering PrEP to patients based on local epidemiology and individual assessment, as opposed to risk group, so that implementation may be informed by local information on the settings and circumstances of HIV transmission. This aims to enable a broader range of populations to benefit from PrEP.

The CDC provide detailed guidelines on the use of PrEP, including in MSM (Table 3).⁷³

Table 3. CDC Guidance on HIV PrEP for MSM⁷³

The CDC clinical guidelines on the use of PrEP includes recommendations for PrEP in at-risk heterosexually active adults (Table 4).⁷³ Note that these recommendations are for individuals who are at an ongoing, very high risk for sexual acquisition of HIV infection, such as those whose partners are known to have HIV infection.

Table 4. CDC Guidance on HIV PrEP for Heterosexually Active Adults at Ongoing, Very High Risk of Sexually Acquired HIV Infection⁷³

The CDC clinical guidelines on the use of PrEP includes recommendations for PrEP in at-risk people who inject drugs (Table 5).⁷³

Table 5. CDC Guidance on HIV PrEP for People Who Inject Drugs⁷³

Current guidelines from the International Antiviral Society (IAS)-USA panel also recommend daily oral PrEP with emtricitabine/tenofovir DF for adult patients at risk for sexual exposure as well as all individuals who inject drugs.⁷⁴ To ensure adequate tissue levels, the IAS-USA panel recommends a 7-day lead-in period with daily oral PrEP before sexual exposure.

Oral PrEP
Based on the positive protective benefit of emtricitabine/tenofovir DF for prevention of HIV in the studies discussed below, in 2012, the FDA approved emtricitabine/tenofovir DF to reduce the risk of sexually acquired HIV infection in adults at high risk, and in 2018, the FDA expanded the indication to include at-risk adolescents. In September 2019, the FDA approved a second 2-drug combination, emtricitabine/tenofovir AF, for PrEP in adults and adolescents weighing at least 35 kg to reduce the risk of HIV infection from sexual acquisition, excluding individuals at risk from receptive vaginal sex.⁷⁵Individuals at risk of HIV acquisition from receptive vaginal sex were excluded from the indication because prevention efficacy data are not yet available in this population.The approval of emtricitabine/tenofovir AF for PrEP is based on comparable prevention efficacy vs emtricitabine/tenofovir DF in men and transgender women who have sex with men demonstrated in the DISCOVER trial.¹¹ The CDC PrEP guidelines have not yet been updated to reflect the availability of this new option.⁷³

Tenofovir DF. The first study of oral tenofovir DF, conducted among 936 women in Ghana, Nigeria, and Cameroon, was designed to evaluate whether oral tenofovir DF taken once daily could reduce the incidence of HIV infection in women.⁷⁶ Although the study was never completed at the Nigeria and Cameroon sites (due to community and political opposition), it nevertheless provided important data supporting the safety of oral tenofovir DF in HIV-uninfected women. There were no differences in clinical or laboratory adverse events between the tenofovir DF and placebo arms. In addition, there was no evidence of increased risk taking (risk disinhibition) associated with the use of oral PrEP. There were 6 HIV infections among women randomized to placebo and 2 among women receiving tenofovir DF (P = NS).

A placebo-controlled safety study of once-daily oral tenofovir DF was completed by the CDC in nearly 400 MSM recruited from Atlanta, San Francisco, and Boston.⁷⁷ Participants were randomly assigned to 1 of 4 study arms. Participants in 2 of the arms received either tenofovir DF or placebo immediately on enrollment, whereas participants in the other 2 arms received either tenofovir DF or placebo 9 months after enrollment. Risk disinhibition was evaluated by recording sexual behavior prior to drug randomization and comparing these data with sexual behaviors after randomization. This study was not powered for efficacy in preventing HIV but did provide new information on the safety and acceptability of daily PrEP among US MSM. The prospective data on sexual disinhibition for this population when taking daily oral PrEP suggested that there was no increase in sexual risk-taking while men were using ARVs for HIV prevention.⁷⁸

Bangkok Tenofovir
The Bangkok Tenofovir Study found that daily oral tenofovir DF PrEP reduced the risk of HIV infection in people who inject drugs.¹⁷ The study enrolled 2413 HIV-negative individuals who reported injecting drugs in the previous year. Participants were randomized to tenofovir DF or placebo and could choose between monthly visits or daily directly observed therapy. Fifty HIV infections occurred during follow-up: 17 in the tenofovir DF group and 33 in the placebo arm, equating to a 48.9% reduction in HIV incidence (95% CI: 9.6% to 72.2%; P = .01). Nausea was more common in the tenofovir DF arm, but the frequency of serious adverse events did not differ significantly between arms.

Emtricitabine/Tenofovir DF. The iPrEx study randomized 2499 HIV-negative men or transgender women who have sex with men to receive a combination of once-daily emtricitabine/tenofovir DF or placebo. Results showed that 64 patients in the placebo arm became infected vs only 36 patients in the emtricitabine/tenofovir DF arm, which reflects a 44% reduction in the incidence of HIV (95% CI: 15% to 63%; P < .001).⁸ Furthermore, for patients who took the drug as directed throughout the trial, emtricitabine/tenofovir DF was nearly 100% effective at preventing HIV acquisition. However, a subanalysis revealed that emtricitabine/tenofovir DF was not effective in the small number of transgendered women in the trial (15% of participants), with 11 infections occurring in each arm.⁷⁹ There was no evidence of an increase in sexual risk behavior during the study according to an analysis that included assessments at baseline, after drug initiation, and through follow-up.⁸⁰ Whereas similar serious adverse event rates were recorded in the 2 study arms, nausea was reported more frequently during the first 4 weeks in the emtricitabine/tenofovir DF arm vs the placebo arm.⁸

Partners PrEP
The Partners PrEP study enrolled 4747 HIV-serodiscordant heterosexual couples from Kenya and Uganda.⁹ The HIV-negative partner in each couple was randomly assigned to tenofovir DF, emtricitabine/tenofovir DF, or placebo for 36 months. However, the placebo arm was terminated early by the data and safety monitoring board due to the finding that both PrEP strategies significantly reduced HIV acquisition vs placebo. Indeed, tenofovir DF decreased HIV acquisition risk by 67% vs placebo (P < .001) and emtricitabine/tenofovir DF decreased the risk by 75% (P < .001). In addition, the risk was decreased in both men and women: The efficacy of tenofovir DF was 71% in women (P = .002) and 63% in men (P = .01), and the efficacy of emtricitabine/tenofovir DF was 66% in women (P = .005) and 84% in men (P < .001). The rates of death, serious adverse events, and laboratory events reported were low and not significantly different between arms, and there were no efficacy differences between the 2 active regimens. The adherence rate as assessed by a return pill count was 97%. As assessed by measurement of tenofovir in the plasma samples collected during study visits, adherence to study tablets exceeded 80%.

TDF2
The TDF2 study randomized 1219 HIV-uninfected, heterosexually active adults in Botswana to emtricitabine/tenofovir DF or placebo for ≥ 12 months of follow-up and found that the overall protective efficacy of emtricitabine/tenofovir DF was 62.2% (95% CI: 21.5% to 83.4%; P = .03).¹⁰ The reduction in HIV acquisition was observed in both men and women, and medication adherence was similar between the study arms. Some adverse events occurred more frequently with emtricitabine/tenofovir DF vs placebo, including nausea (18.5% vs 7.1%; P < .001), vomiting (11.3% vs 7.1%; P = .008), and dizziness (15.1% vs 11.0%; P = .03), but rates of serious adverse events were similar between arms.

IPERGAY and PROUD
In early 2015, data from 2 additional clinical trials, IPERGAY, conducted in France, and PROUD, conducted in the United Kingdom, likewise demonstrated that emtricitabine/tenofovir DF given as PrEP is highly effective in reducing HIV transmission in HIV-negative MSM; a finding that prompted the data and safety monitoring boards from both trials to recommend allowing all study participants to receive emtricitabine/tenofovir DF.⁸¹ In the PROUD trial, which was initially only intended to be a pilot study to determine the feasibility of a larger study, 544 HIV-uninfected participants were randomized 1:1 to receive oral emtricitabine/tenofovir DF either immediately or deferred until after 12 months.⁸² At the time of analysis, 465 patient-years had been accrued. The incidence of HIV infection was 1.2/100 patient-years in the immediate PrEP arm compared with 9.0/100 patient-years in the deferred arm, demonstrating an 86% reduction in HIV transmission (90% CI: 64-96; P = .0001). Based on these results, it was found that 13 men in a similar population would need to receive this PrEP for 1 year to avert 1 HIV infection. Overall, 28 patients interrupted PrEP, 13 for drug-related events, and 20 of 21 were able to restart PrEP.

In the IPERGAY trial, 414 HIV-uninfected participants were given oral emtricitabine/tenofovir DF or placebo “on demand” at the time of sexual exposure with a schedule of 2 tablets 2-24 hours before sex, 1 tablet 24 hours later, and another tablet 24 hours after the second dose, or the option of daily usage for frequent exposures.⁸³ After showing early efficacy, the trial was subsequently amended to offer PrEP to all participants. All participants had a median of 9 months follow up. A median of 15 tablets were taken per month per patient. The incidence of HIV transmission was 6.6/100 patient-years in patients taking placebo compared with 0.91/100 patient-years in patients taking PrEP, demonstrating a relative reduction of 86% (95% CI: 40% to 98%; P = .002). Correct use of PrEP was reported for 43% of sexual acts in the PrEP arm and for 40% of sexual acts in the placebo arm. The rate of serious adverse events was similar in both arms. This trial demonstrates that PrEP given “on demand” can be highly effective and could provide a good alternative to a daily regimen of emtricitabine/tenofovir DF to improve adherence and reduce HIV transmission rates in high risk populations such as MSM with high risk profiles. It should be noted however, that the study population in the IPERGAY trial took emtricitabine/tenofovir DF a median of 16 days (12-24 days) each month, a frequency of tenofovir DF usage that was associated with decreased risk of HIV infection (Table 6).⁸⁴

The current IAS-USA guidelines include pericoital, or on-demand, oral emtricitabine/tenofovir DF as an alternative PrEP option for MSM with infrequent sexual exposure.⁷⁴ Dosing should follow the “2-1-1” strategy used in the IPERGAY trial: 2 emtricitabine/tenofovir DF tablets taken with food 2-24 hours before sex, followed by 1 tablet taken 24 hours after the first (doubled) dose, and then 1 more tablet 24 hours later. The guidelines panel recommends that the first (doubled) emtricitabine/tenofovir DF dose should be taken closer to the 24-hour precoital time point than the 2-hour time point. Note that on-demand PrEP is not recommended for other groups at risk for HIV infection or in those with active HBV infection.

Table 6. Effect of Tenofovir Levels in Dried Blood Spots on HIV Infection Incidence⁸⁴

Partners Demonstration Project
Similar efficacy results with PrEP were also seen in another ongoing prospective trial, The Partners Demonstration Project, in which serodiscordant heterosexual couples in Africa were offered ART to the partner with HIV regardless of CD4+ cell count and PrEP with emtricitabine/tenofovir DF to the uninfected partner until the partner with HIV reached 6 months of ART therapy.³³ At the time of analysis (858 person-years accrued), 2 cases of HIV transmission had occurred demonstrating a 96% (95% CI: 81-99; P < .001) reduction in risk of HIV transmission. In both cases of HIV transmission, the HIV-uninfected partner reported interruptions in PrEP use and tenofovir was undetectable in plasma samples at the time of seroconversion.

HPTN 067/ADAPT
The randomized HPTN 067/ADAPT trial has also evaluated nondaily, time-driven or event-driven oral emtricitabine/tenofovir DF PrEP in several different cohorts, including MSM and transgender women in Bangkok, Thailand, and in Harlem, New York, and women in Cape Town, South Africa. In this trial, participants began with a lead-in 6-week period of directly observed therapy, after which they were randomized to one of 3 arms for 24 weeks of self-administered dosing: continuous once-daily PrEP, time-driven PrEP (1 dose twice weekly plus 1 dose after sex), or event-driven PrEP (1 dose before sex and 1 dose after sex). Coverage of sex acts (vaginal and anal), defined as taking ≥ 1 PrEP pill within 4 days before having sex and ≥ 1 PrEP pill within 24 hours following sex, was a primary endpoint of the trial. The results differed based on the cohort. In the United States (Capsule Summary) and South African cohorts, continuous daily dosing provided better coverage of sex acts and higher adherence vs time-driven or event-driven PrEP.^85,86 However, in the Bangkok cohort, time-driven PrEP provided coverage of sex acts comparable to daily dosing whereas event-driven PrEP was associated with lower coverage of sex acts (Capsule Summary).⁸⁷ Adherence was higher with daily vs time-driven PrEP, but the difference was not statistically significant; adherence to event-driven PrEP was significantly lower than each of the other 2 arms. It is important to note that coverage of sex acts as defined in HPTN 067/ADAPT has not been demonstrated to be an effective PrEP strategy (ie, 1 pill up to 4 days before and 1 pill up to 24 hours after sex). Investigators concluded that the results of this trial generally support current recommendations for continuous daily oral PrEP dosing.

Prevenir
Further data supporting the efficacy of both daily and on-demand PrEP with oral emtricitabine/tenofovir DF come from an interim analysis of the open-label prospective ANRS Prevenir trial. In this study, a cohort of predominantly MSM in the Paris region at high risk of HIV acquisition and with inconsistent condom use were given the option of daily vs on-demand (≥ 1 pill < 24 hours before and 1 pill < 24 hours after sex) oral emtricitabine/tenofovir DF PrEP.⁸⁸ No incident HIV infections were observed during a mean follow-up of 7 months at the time of the interim analysis, which included 724 participants receiving daily PrEP and 870 receiving on-demand PrEP (Capsule Summary).

FEM-PrEP
Studies evaluating tenofovir DF–based PrEP have not been consistently positive. In the FEM-PrEP study, which evaluated the protective effect of emtricitabine/tenofovir DF vs placebo in 2120 HIV-negative women in Kenya, South Africa, and Tanzania, emtricitabine/tenofovir DF did not significantly reduce the rate of infection compared with placebo, and it was associated with significantly increased rates of nausea (P = .04), vomiting (P < .001), and alanine aminotransferase elevations (P = .03).¹⁵However, adherence rates in this study were low, with recent pill use evident in < 27% of women who acquired HIV infection and < 38% in matched uninfected controls.⁷³ The authors suggested that the low adherence rates may partially account for the lower efficacy of emtricitabine/tenofovir DF in heterosexual women in the FEM-PrEP trial compared with the Partners PrEP and TDF2 trials.⁷³Of note, a high proportion of women in this study did not perceive themselves to be at risk for infection, which might have negatively affected their adherence to prophylactic therapy.

One hypothesis that has been proposed as an explanation for the discordance between the efficacy of PrEP in the FEM-PrEP¹⁵ and VOICE trials compared with the iPreX and Partners PrEP trials is that efficacy may be lower in populations who have a higher incidence of HIV infection. Investigators reported data from an analysis aimed at addressing this possibility by evaluating the efficacy of PrEP within higher-risk subgroups in the Partners PrEP trial, including high-risk female subgroups.⁸⁹ The results showed that within high-risk subgroups of women who experienced an HIV infection rate > 5 per 100 person-years in the placebo arm (compared with 2 per 100 person-years for overall placebo arm), the efficacy of tenofovir DF or emtricitabine/tenofovir DF for protecting against HIV infection was estimated to range from 64% to 84% (all P < .05). All subgroups demonstrated > 94% attendance rates for monthly visits and tenofovir DF detection rates > 70% for random plasma samples. These findings indicate that when adherence rates are high, PrEP is highly effective even in high-risk heterosexual subgroups. Additional research is under way to explain the discordant results in the PrEP trials. However, it is clear that the low level of adherence to daily prevention regimens, both oral and topical, among younger and unmarried women in the FEM-PrEP and VOICE trials who had the highest risk of HIV likely accounts for the difference in the results. Although daily medication use for people in HIV-serodiscordant partnerships was highly acceptable to the couples participating in Partners PrEP, many young unmarried women who are unaware of the HIV status of their sex partners likely need different options for prevention of HIV.

ATN113
Between August 2013 and September 2014, 78 HIV-uninfected adolescent MSM (aged 15-17 years) who self-reported high-risk sexual behavior were enrolled in the ATN113 trial conducted in 6 cities across the United States. The open-label study evaluated the safety of emtricitabine/tenofovir DF as PrEP for 48 weeks in combination with counseling on safer sex practices. Self-reported high-risk behaviors included anal intercourse without the use of a condom with a partner with HIV or of unknown status, ≥ 3 male sex partners, exchange of goods or services for sex, and intercourse with a male with a known sexually transmitted infection. The study found that emtricitabine/tenofovir DF was well tolerated with unintended grade 3 weight loss being the most severe adverse event (n = 2).^90,91 A decrease in bone mineral density occurred in 4 participants (modest decrease in 3 participants and > 4% decline in 1 participant).⁹¹ Three participants acquired HIV during the course of the study. The annualized HIV incidence was 6.4 per 100 person-years (95% CI: 1.3-18.7).⁹⁰ Tenofovir diphosphate blood levels in each of the participants who acquired HIV during the study were consistent with suboptimal adherence (fewer than a mean of 2 doses per week).⁹¹ No genotypic mutations associated with resistance to tenofovir DF or emtricitabine were detected. Dried blood assays of tenofovir diphosphate (TFV-DP) levels also demonstrated a marked decline in overall adherence levels after Week 12 of the study when participant clinic visits switched from monthly to quarterly. This finding suggests that additional adherence support may be needed for adolescents receiving PrEP. The results of ATN113 in combination with the well-established safety and efficacy of this combination for PrEP in adults led the FDA to expand the indication for daily oral emtricitabine/tenofovir DF PrEP in combination with safer sex practices to include use in at-risk adolescents weighing ≥ 35 kg.⁹¹

Pharmacokinetics of Emtricitabine/Tenofovir DF PrEP. Several pharmacokinetic analyses have contributed to a better understanding of both the onset and duration of oral PrEP activity. Results from the CellPrEP study demonstrated that 89% of participants (21 HIV-uninfected volunteers) reached a 90% effective concentration of TFV-DP in peripheral blood mononuclear cells after 7 days of daily oral emtricitabine/tenofovir DF.⁹² In addition, the inferred HIV risk reduction based on TFV-DP concentrations remained > 90% for 7 days after stopping PrEP. Of note, the inferred risk reduction estimations in CellPrEP were based on data obtained from drug concentrations and efficacy in MSM enrolled in the iPrEx study; therefore, the findings cannot be extrapolated to heterosexual men, women, or HIV transmission via other routes. In a pharmacokinetic substudy of IPERGAY, samples were taken during a 24-hour period from 12 participants who received a single double-dose of oral emtricitabine/tenofovir DF. Emtricitabine was detected at high concentrations (comparable to levels in patients receiving emtricitabine-containing ART) in rectal tissue samples as early as 30 minutes after dosing, whereas tenofovir was not detected at comparable concentrations until 24 hours post dosing.⁹³ When investigators assessed ex vivo HIV infectivity of rectal biopsies from 10 substudy participants, the results showed that the double-dose of emtricitabine/tenofovir DF reduced the proportion of patients with rectal tissue samples susceptible to HIV infection (vs samples taken before dosing) but did not eliminate susceptibility, suggesting that postexposure doses are required in addition to the pre-exposure double dose to achieve full protection.

Tenofovir AF. Tenofovir AF is an alanine ester prodrug of tenofovir that is characterized by reduced systemic levels of tenofovir. Tenofovir AF is largely delivered as tenofovir AF to lymphocytes and macrophages and then metabolized intracellularly to tenofovir and phosphorylated to the active TFV-DP. This pathway contrasts with that of tenofovir DF, which is converted to tenofovir in the blood, then taken up by cells. Compared with tenofovir DF, plasma tenofovir levels after oral administration of tenofovir AF are 90% lower, whereas intracellular concentrations of tenofovir are up to 20-fold higher, allowing for lower dosing compared with tenofovir DF and reduced toxicity.⁹⁴

DISCOVER
In the phase III DISCOVER trial, emtricitabine/tenofovir AF was compared with emtricitabine/tenofovir DF for daily oral PrEP in cis-MSM and transgender women at high risk of HIV infection. The primary endpoint of HIV incidence per 100 patient-years was 0.16 for emtricitabine/tenofovir AF vs 0.34 for emtricitabine/tenofovir DF, establishing the noninferiority of emtricitabine/tenofovir AF, with an HIV incidence rate ratio of 0.47 (95% CI: 0.19-1.15). While both PrEP regimens were well tolerated with low rates of discontinuation for AEs (1% to 2%), emtricitabine/tenofovir AF was linked with significantly improved renal and bone safety outcomes at Week 48 vs emtricitabine/tenofovir DF.¹¹

Further analyses of data from the DISCOVER trial to identify factors contributing to the apparent numerically decreased HIV infection rate observed with emtricitabine/tenofovir AF vs emtricitabine/tenofovir DF as PrEP found that the intracellular TFV-DP concentrations in peripheral blood mononuclear cells were 6.3-fold higher with emtricitabine/tenofovir AF vs emtricitabine/tenofovir DF (Capsule Summary).⁹⁵ At Week 4, peripheral blood mononuclear cell TFV-DP EC₉₀ was reached by 98% of patients receiving emtricitabine/tenofovir AF vs 68% of patients receiving emtricitabine/tenofovir DF. EC₉₀ was reached within 1-2 hours of the first emtricitabine/tenofovir AF dose vs after 3 daily doses of emtricitabine/tenofovir DF. A simulation indicated that concentrations greater than the EC₉₀ would last for 16 days after the final dose of emtricitabine/tenofovir AF vs only 10 days after discontinuation of emtricitabine/tenofovir DF.

Oral PrEP Implementation. Despite data demonstrating high efficacy of oral PrEP within the context of a clinical trial, additional data have accrued on practical aspects of PrEP implementation in a community setting, particularly regarding real-world adherence and behavioral risk compensation. The US PrEP Demonstration Project was a prospective, open-label, cohort study designed to evaluate PrEP uptake, adherence, efficacy, and safety as well as sexual risk behavior and HIV resistance among HIV-negative MSM and transgender women (N = 557) receiving care at STD clinics and community-based health clinics in 3 US cities: San Francisco, Miami, and Washington, DC. After 481 person-years of follow-up, the results demonstrated relatively high rates of adherence, particularly among participants at higher risk (those with ≥ 2 condomless anal sex partners in the previous 3 months) (Capsule Summary).⁹⁶ Overall, 63% of participants had protective levels of TFV-DP in dried blood spot at all study visits. Black participants and participants at the Miami site had significantly lower adherence levels, as measured by the proportion of participants with protective TFV-DP levels in dried blood spots at the end of the study, compared with white participants and the San Francisco site. The rate of HIV infection was low at 0.43/100 person-years during the follow-up period despite a high STD incidence rate (90/100 person-years).

Another open-label feasibility study, ATN 110, evaluated PrEP uptake, safety, adherence, and effects on sexual risk taking in 200 HIV-uninfected US MSM aged 18-22 years who were receiving an additional informational or behavioral intervention to prevent HIV infection in community-based settings. In this trial, daily oral PrEP was generally safe and well tolerated, with only 3 adverse events (all grade 3) considered to be related to study treatment.⁹⁷ Adherence based on TFV-DP levels decreased over time, particularly when the frequency of study visits decreased from every 4 weeks to every 12 weeks (between Week 12 and 24). Adherence levels were lowest in black men throughout the study. In this trial, participants reporting condomless anal intercourse during the study showed higher adherence levels (P = .01), suggesting that individuals who are at the greatest risk of infection may also be most likely to adhere to PrEP. The HIV incidence rate was 3.29/100 person-years; all 4 participants who acquired HIV infection during the study had undetectable TFV-DP levels at the time of HIV diagnosis.

Maraviroc. Another ARV agent evaluated for the prevention of HIV is maraviroc. The randomized, double-blind NEXT-PrEP study evaluated the safety and efficacy of maraviroc alone or with emtricitabine or tenofovir DF, compared with emtricitabine/tenofovir DF, in MSM and at-risk women in the United States and Puerto Rico (<a rel="noopener noreferrer" rel="noopener noreferrer" href="https

BACK | NEXT

Clinical Education Alliance Terms and Conditions

These Terms of Use ("Terms") apply to your use of the websites, mobile applications and other resources provided by Clinical Education Alliance LLC (“CEA”) and its affiliates (referred to collectively as "CEA," "us," "we" and "our") that are intended for use by healthcare professionals, which we refer to as the "CEA Network," including the personalized information and services that meet the needs and interests of users of the CEA Network such as medical news, reference content, clinical tools, applications, sponsored programs, advertising, email communications, continuing medical education, market research opportunities and discussion forums (collectively, the "Services"). You will always be able to view the most current version of these Terms by clicking on the Terms of Use link at the bottom of any page of a CEA Network property. Note that these Terms do not apply to our properties and services that display a link to different terms of use. In the event that we expand the CEA Network through our acquisition of another company and/or its properties, that company may operate its properties subject to its own terms of use accessible via a link on such properties until we integrate its practices with ours, at which point a link to these Terms will be displayed on its properties. By using the Services, you agree to these Terms, whether or not you are a registered member of the CEA Network. These Terms govern your use of the Services and create a binding legal agreement that we may enforce against you in the event of a violation. If you do not agree to all of these Terms of Use, do not use the Services!

We reserve the right to change these terms from time to time. The most current version may be viewed by clicking on the “Terms of Use” link at the bottom of designated pages on the Clinical Education Alliance Sites. Use of the Clinical Education Alliance Sites after the effective date constitutes acceptance of the amended Terms of Use. When you leave a CEA Web site and go to another Web site, different terms apply and CEA has no responsibility or liability for any content on those sites.

Clinical Education Alliance Content

The Clinical Education Alliance Sites incorporate information, including modules, capsules, journal articles, medical news, references, interactive case studies, other continuing education material, downloadable software applications, advertising, and other healthcare information, which is intended for adults who are licensed healthcare professionals. This information is not intended to serve as a substitute for the healthcare professional’s clinical judgment. If you are a consumer who chooses to read this professional-level information on Clinical Education Alliance Sites, you should not use or rely on that information as professional medical advice or use it to replace any relationship with your physician or other qualified healthcare professional or any information they may have provided to you. For medical issues or concerns, including decisions about medications and other treatments, consumers should always consult their physician or, in serious cases, seek immediate assistance from emergency personnel.

The Content on the Clinical Education Alliance Sites is developed or selected in accordance with our published Editorial Policies. However, users access and use this material at their own risk. It is the reader’s job to evaluate the accuracy of any information and results from interactive programs found on the Clinical Education Alliance Site. If you are a healthcare professional, you should rely on your professional judgment in evaluating any and all information and confirm the information contained on the Clinical Education Alliance Sites with other sources and reliable third parties before basing any treatment or advice on it. If you are a consumer, you should evaluate the information together with your physician or another qualified healthcare professional.

DISCLAIMERS AND LIMITATIONS OF LIABILITY

THE CONTENT, APPLICATIONS, SOFTWARE, AND ALL OTHER MATERIAL ON THE CLINICAL EDUCATION ALLIANCE SITES ARE PROVIDED “AS IS” AND WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NONINFRINGEMENT. ALL WARRANTIES, EXPRESS OR IMPLIED, ARE HEREBY DISCLAIMED. CLINICAL EDUCATION ALLIANCE SHALL NOT BE LIABLE FOR ANY SPECIAL, INCIDENTAL, OR CONSEQUENTIAL DAMAGES, INCLUDING, WITHOUT LIMITATION, PHYSICAL HARM OR INJURIES, LOST REVENUES, OR LOST PROFITS, RESULTING FROM THE USE OR MISUSE OF THE CLINICAL EDUCATION ALLIANCE SITES, OR ANY INFORMATION, APPLICATIONS, MATERIALS, OR SOFTWARE THEREON, EVEN IF CLINICAL EDUCATION ALLIANCE HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, OR FOR ANY CLAIM BY ANOTHER PARTY. CLINICAL EDUCATION ALLIANCE DOES NOT WARRANT THAT THIS SITE OR ANY APPLICATIONS OR SOFTWARE WILL BE FREE OF BUGS, INACCURACIES, OR ERRORS, NOR DOES CLINICAL EDUCATION ALLIANCE WARRANT THAT ANY SITE, SOFTWARE, OR APPLICATION IS FREE OF VIRUSES OR OTHER HARMFUL ELEMENTS.

A user’s use of the Clinical Education Alliance Sites, and any reliance on any materials, information, software, or applications, is at the user’s own risk. You agree that you hereby release Clinical Education Alliance and its affiliates, owners, respective directors, officers, employees, advertisers, authors, and contributors from any and all liability or obligations arising from the use of the Clinical Education Alliance Sites. A user’s sole remedy for any problem or concern is to exit the Web site or application. You agree that you will indemnify and hold Clinical Education Alliance harmless for any loss, damages, or liability suffered by Clinical Education Alliance as a result of your use of any Clinical Education Alliance Site or material, application, information, or software thereon or your submission of any material to Clinical Education Alliance. Clinical Education Alliance reserves the right to restrict or limit access to this Web site.

CEA Programs, Tools, and Databases

The Clinical Education Alliance Sites include interactive programs, clinical tools, and databases intended for the use of healthcare professionals. These materials are not intended as professional advice or recommendations of particular products. Physicians and other healthcare professionals who use our interactive programs, tools, or databases should exercise their own clinical judgment as to the results. Consumers who use the tools or databases do so at their own risk.

Individuals with any type of medical condition are specifically cautioned to seek professional medical advice before beginning any sort of health treatment. For medical concerns or issues, including decisions about medications and other treatments, users should always consult their physician or other qualified healthcare professional.

Ownership of Clinical Education Alliance Sites—Copyright and Trademarks

The entire contents and design of the Clinical Education Alliance Sites, including the software applications, tools, and databases, are protected under US and international copyright laws. These materials are owned by CEA or its affiliates or are used with permission of their owners or as otherwise authorized by law. All rights are reserved, worldwide. You may look at the Clinical Education Alliance Sites, download individual articles or applications to your personal computer or handheld device, and print a reasonable number of pages for your own personal reference. You must not remove any copyright notices from our materials. We reserve all our other rights. This means you may not sell, rewrite, or modify any content or other material found on any Clinical Education Alliance Site, redistribute it, put it on your own Web site, or use it for any commercial purpose without our prior written authorization.

The names of the CEA products and services are protected by trademark laws in the United States. Any use of our trademarks or service marks requires prior written approval from CEA.

You may link to a CEA Web site if your Web site offers products, services, or information of interest to the professional healthcare community. You are not allowed to link to the Clinical Education Alliance Sites if you post illegal, obscene, or offensive content or if the link is likely to have a negative impact on CEA’s reputation. Any other use, such as framing any part of a CEA Web site or incorporating any CEA content into another Web site, product, or application, requires advance written permission from Clinical Education Alliance. Clinical Education Alliance assumes no responsibility for any Web sites or materials that are linked to Clinical Education Alliance Sites or materials.

Software Products and Applications

Clinical Education Alliance makes some software and accompanying documentation available for downloading from our Web sites and/or from iTunes. These materials are protected by copyrights under US and international law and are owned by Clinical Education Alliance or companies that have licensed the software to us. We do not transfer any ownership rights in software or documentation to you when you download it from our Web site and/or directly from iTunes. You may use the software and accompanying documentation for their intended purpose. You are not authorized to further copy or distribute the software and accompanying documentation, nor may you attempt to recreate or reverse engineer our software or applications. In addition, some software available for downloading from our Web sites and/or from iTunes is subject to US export controls. By downloading or using such software, you are representing to us that your download of such software complies with these controls.

US Government End Users

If you are affiliated with the US government, please note that the software and documentation available on our Web sites and/or directly from iTunes are “commercial items,” as that term is defined in 48 C.F.R. 2.101 (October 1995), consisting of “commercial computer software” and “commercial computer software documentation,” as such terms are used in 48 C.F.R. 12.212 (September 1995). Consistent with 48 C.F.R. 12.212 and 48 C.F.R. 227.7202-1 through 227.7202-4 (June 1995), all US government end users acquire the software and documentation with only those rights set forth herein.

Social Media, Message Boards, and Forums

Clinical Education Alliance offers users the opportunity to engage in social media interactions with both experts and other users of the sites. As with other online social media, users must exercise sound judgment in both the information that they post and in how they assess the postings of other users. As such, users are expected to adhere to the social media recommendations made by the American Medical Association when utilizing the social media capabilities of CEA sites. In particular, users must be cognizant of standards of patient privacy and confidentiality that must be maintained in all environments and must not post identifiable patient information on CEA sites. In social media interactions, users must maintain appropriate boundaries of the patient–physician/care provider relationship in accordance with professional ethical guidelines just as they would in any other context. Users acknowledge that privacy settings are not absolute and that once on the Internet, content posted by them may be copied by third parties and republished out of the control of Clinical Education Alliance. Thus, users should routinely monitor their own Internet presence to ensure that the personal information and content that they post and, to the extent possible, that is posted about them by others is accurate and appropriate.

Users are expected to refrain from submitting comments or messages that are defamatory, hateful, or obscene or that harass others. Users may not impersonate any other person or violate any other person’s or entity’s legal rights or submit falsified credentials or experiences. Users agree that they will not submit any materials that violate or infringe any copyrights, trademarks, patents, trade secret, or other intellectual property rights of any third party. Clinical Education Alliance retains all copyrights in the content posted by users to its sites. Clinical Education Alliance may adopt additional rules to govern use of social media, message boards or forums, to which users will be subject.

Copyright and Other Legal Violations

If you believe that any material on this Web site infringes your copyright, please notify us as follows, under the Digital Millennium Copyright Act (“DMCA”). To notify us, the DMCA requires that you: 1. Send an email notice to Clinical Education Alliance at customersupport@clinicaloptions.com. 2. Include the following information in your email: a. Identify the copyrighted work(s) you claim is infringed; b. Identify the material you claim is infringing the copyright(s) and give enough information for Clinical Education Alliance to locate that material; c. Include a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf (the “Claimant”); d. Include the Claimant’s name, address, and telephone number(s); e. Include a statement that the Claimant has a good faith belief that use of the disputed material is not authorized by the copyright owner or his agent; and f. Include a statement, under penalty of perjury, that the information in the notification of copyright infringement is accurate and that the Claimant is the copyright owner or is authorized to act on behalf of the copyright owner.

If you believe any content or material on the Clinical Education Alliance Sites violates any laws, please notify customersupport@clinicaloptions.com. Please include details about your concerns and an email address for contacting you.

Governing Law

Clinical Education Alliance controls the Clinical Education Alliance Sites from its offices in the state of Virginia in the United States of America. The Clinical Education Alliance Sites can be accessed from any of the United States and from other countries worldwide. Since the laws of each state or country may differ, both you and Clinical Education Alliance agree that the laws of Virginia, without regard to conflicts of laws principles, will apply to all matters relating to use of the Clinical Education Alliance Sites and materials, including software and applications.

Clinical Education Alliance makes no representation that materials on these sites are appropriate or available for use in countries aside from the United States. Accessing the Clinical Education Alliance Sites from territories where their contents are illegal is prohibited. Those who choose to access these sites from other locations do so at their own risk and are responsible for compliance with any and all applicable local laws or regulations.

Acceptance Procedure

By downloading or accessing materials on the Clinical Education Alliance Sites and/or directly from iTunes or registering with us, you agree to all the terms and conditions in this agreement, including the Terms of Use and Privacy Policy. If you disagree with any of these Terms of Use or Privacy Policy, please refrain from using the Clinical Education Alliance Sites or materials.

Privacy Policy

Because we provide education for healthcare professionals, we pay special attention to privacy issues. The purpose of our Privacy Policy is to identify the information we may collect about you, describe the uses we may make of your information and the security measures we take to protect it, and discuss your options for controlling your information. You can review our Privacy Policy by clicking on the “Privacy Policy” link at the bottom of designated pages on the Clinical Education Alliance Sites.

Disputes

If you fail to comply with these terms, we have the right to suspend or eliminate your account and remove any information you have placed on our site, including your registration information. We may also take any legal action we think is appropriate. If there is any dispute between us concerning this agreement or your use of any Clinical Education Alliance Site or materials or applications, we both agree to submit the dispute to nonbinding mediation, followed by binding arbitration. Both the mediation and the arbitration will be governed under the rules of the American Arbitration Association, and the venue for the arbitration will be Virginia.

Questions or Concerns About Our Terms of Use

For questions or concerns about these Terms of Use, please send an email to customersupport@clinicaloptions.com

These terms of use were last updated in July 2021.